Use of MenAfriVac™ (‎meningitis A vaccine)‎ in a controlled temperature chain (‎CTC)‎ during campaigns : adaptation guide and facilitators guide

Overview

The need to keep vaccines in a 2°C to 8°C cold chain is a constraining factor for many immunization campaigns due to limited storage capacity and/or limited ice pack freezing capacity; supplementary immunization activities planned across sub-Saharan Africa to introduce MenAfriVac™ are a good example. In 2012, the license for the Serum Institute of India’s meningitis A vaccine, MenAfriVac®, was changed based on a thorough review of scientific data by regulatory authorities and the World Health Organization (WHO) to allow for the use of the vaccine for a period of up to 4 days at temperatures of up to 40°C in a controlled temperature chain (CTC). This document provides countries with guidance on when and how to take advantage of this flexibility.

There are three publications in this series.

This publication is the adaptation guide and facilitators guide.